Coalesce Product Development

Coalesce Product Development is developing new inhalation devices focused on certain capabilities of combined products.

History

2022

Sandoz bought respiratory device developer

In mid-March 2022, Sandoz announced the acquisition of Coalesce Product Development, a developer of respiratory devices and drug delivery equipment. The financial and other terms of the agreement are not disclosed.

As a result of the transaction, Sandoz acquired Coalesce's capabilities and assets, which in turn will help Novartis's division strengthen its existing respiratory drug portfolio and further expand patients' access to comprehensive treatment.

Sandoz bought respiratory device developer Coalesce Product Development

The Sandoz portfolio for March 2022 contains six products already on the market, and another 12 products in development. The company considers respiratory issues an important aspect of its long-term growth strategy and plans to explore more opportunities both within and outside its business through mergers and acquisitions of other companies. Sandoz also plans to expand its portfolio in comprehensive generics, including injectable drugs.

"Respiratory drugs and complex generics are areas with relatively high unmet medical need, largely because of their relatively high technical complexity. Sandoz has the expertise and knowledge necessary to work successfully in these areas, and this acquisition gives us a significant platform for growth, especially in the US and Europe, strengthening our desire for innovative access for patients, "said Sandoz CEO Richard Saynor.

Asthma is one of the major non-communicable diseases affecting both children and adults. Inflammation and narrowing of the small airways in the lungs cause symptoms of asthma, which can be coughing, wheezing, shortness of breath and feeling compressed in the chest in any combination. The burden of respiratory diseases on health systems and labor productivity annually exceeds $380 billion in 28 European Union member states. Sandoz aims to improve asthma diagnosis, treatment and monitoring, reduce the global burden, and make progress towards universal health coverage in the global market.^[1]

Notes